Eli Lilly and Company (LLY) and Incyte (INCY) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion for Olumiant for the treatment of adolescents with severe alopecia areata. AA is a chronic immune disease that can have an especially devastating social and emotional impact on young patients and their families, as early onset AA can be more severe and lead to extensive and unpredictable hair loss. Lilly has also submitted Olumiant in the U.S. for approval to treat severe AA in adolescents, with a decision expected in the second half of 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Eli Lilly, Nvidia Launch LillyPod: Pharma’s First ‘AI Factory’ in Indianapolis
- Private Markets: World Labs raises $1B in new funding
- Soleno Therapeutics CFO Mackaness to retire, Fulk to succeed
- Eli Lilly publishes ACHIEVE-3 trial results in The Lancet
- Eli Lilly’s Oral Obesity Drug Trial Reaches Completion, Sharpening Investor Focus on LLY